Exploring the Impact of Efavirenz on Aflatoxin B1 Metabolism: Insights from a Physiologically Based Pharmacokinetic Model and a Human Liver Microsome Study

Physiologically based pharmacokinetic (PBPK) models were utilized to investigate potential interactions between aflatoxin B1 (AFB1) and efavirenz (EFV), a non-nucleoside reverse transcriptase inhibitor drug and inducer of several CYP enzymes, including CYP3A4. PBPK simulations were conducted in a No...

Descrición completa

Detalles Bibliográficos

Principais autores:	Orphélie Lootens, Marthe De Boevre, Elke Gasthuys, Sarah De Saeger, Jan Van Bocxlaer, An Vermeulen
Formato:	Artigo
Idioma:	Inglês
Publicado:	MDPI AG 2024-06-01
Series:	Toxins
Assuntos:	mycotoxins CYP450 enzymes pharmacokinetics in vitro efavirenz LC-MS/MS
Acceso en liña:	https://www.mdpi.com/2072-6651/16/6/259
Tags:	Engadir etiqueta Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!